Intra-cellular Therapies Inc Sentiment Worsening on Low Stock Potential

June 18, 2018 - By reb123z

Sentiment for Intra-cellular Therapies Inc (NASDAQ:ITCI)

Intra-cellular Therapies Inc (NASDAQ:ITCI) institutional sentiment decreased to 0.96 in 2018 Q1. Its down -0.50, from 1.46 in 2017Q4. The ratio dropped, as 55 active investment managers increased and opened new holdings, while 57 reduced and sold stakes in Intra-cellular Therapies Inc. The active investment managers in our partner’s database now hold: 38.33 million shares, up from 37.43 million shares in 2017Q4. Also, the number of active investment managers holding Intra-cellular Therapies Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 17 Reduced: 40 Increased: 34 New Position: 21.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $1.12 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

The stock decreased 1.16% or $0.24 during the last trading session, reaching $20.39. About 316,546 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has risen 115.54% since June 18, 2017 and is uptrending. It has outperformed by 102.97% the S&P500.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on August, 8. They expect $-0.77 earnings per share, down 87.80 % or $0.36 from last year’s $-0.41 per share. After $-0.65 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts 18.46 % negative EPS growth.

Rhenman & Partners Asset Management Ab holds 2.06% of its portfolio in Intra-Cellular Therapies, Inc. for 792,730 shares. Bb Biotech Ag owns 2.20 million shares or 1.28% of their US portfolio. Moreover, Clough Capital Partners L P has 1.01% invested in the company for 499,624 shares. The Utah-based Wasatch Advisors Inc has invested 0.51% in the stock. Pointstate Capital Lp, a New York-based fund reported 1.87 million shares.

Since January 1, 0001, it had 0 insider purchases, and 9 insider sales for $1.97 million activity.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Ratings analysis reveals 100% of Intra-Cellular Therapies’s analysts are positive. Out of 8 Wall Street analysts rating Intra-Cellular Therapies, 8 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2500 while the high is $34.0. The stock’s average target of $28 is 37.32% above today’s ($20.39) share price. ITCI was included in 13 notes of analysts from February 8, 2018. Cowen & Co maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Thursday, March 1 with “Buy” rating. The rating was maintained by Cantor Fitzgerald on Thursday, May 3 with “Buy”. The firm earned “Buy” rating on Wednesday, June 6 by Cantor Fitzgerald. The firm has “Buy” rating by Canaccord Genuity given on Thursday, March 1. The company was maintained on Monday, April 2 by Cantor Fitzgerald. SunTrust maintained the shares of ITCI in report on Friday, March 2 with “Buy” rating. The stock has “Buy” rating by J.P. Morgan on Monday, February 26. On Thursday, March 1 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The rating was maintained by Leerink Swann on Tuesday, April 3 with “Buy”. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, March 1.

More important recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Globenewswire.com which released: “Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical …” on May 29, 2018, also Nasdaq.com published article titled: “Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms …”, Nasdaq.com published: “New Research: Key Drivers of Growth for CSW Industrials, Cavco Industries, Intra-Cellular Therapies, Atrion, QAD, and …” on May 24, 2018. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was released by: Streetinsider.com and their article: “Intra-Cellular Therapies (ITCI) Highlights Data on Symptom Improvement by Lumateperone on Negative Symptoms …” with publication date: May 31, 2018.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: